17 GHP Q2 2026 atural teeth are surrounded by a soft-tissue defence barrier. This barrier protects the surrounding dental tissue from plaque and oral pathogens and is therefore essential for oral health. When a tooth is lost, this natural defence is also lost. Dental implants are unable to restore this critical protection, leaving an open pathway between implant surface and surrounding soft tissue through which plaque and bacteria enter the tissue, penetrate towards deeper layers, and trigger disease. The result is a high prevalence of inflammatory conditions such as mucositis and peri-implantitis. Symbionic Teeth represent an advanced tooth replacement technology engineered to address this very issue. Symbionic Teeth are comparable to dental implants in that they too are medical devices anchored in the jawbone and restored with crowns for tooth replacement. However, while dental implants achieve only “osseointegration” (the functional connection between the living bone and the surface of an implant), Symbionic Teeth also establish a defence barrier at the level of the gum tissue, thereby restoring the natural protective mechanism of a lost tooth. This represents the next step in the evolution of dental implants. Marco Waldner explains: “As the first tooth replacement solution, Symbionic Teeth have been shown in histological analyses by leading researchers to establish a mucosal defence barrier. This can prevent plaque from migrating into surrounding tissue – which we know is a key driver of inflammation in dental implants.” According to Waldner, this opens up new clinical possibilities for dentists offering tooth replacement therapy. “This technology demonstrates that we do not have to accept that a replacement tooth performs worse by default than a natural tooth.” As a result of this unique tissue protection, the risk of biological side effects typically associated with dental implants is minimised with Symbionic Teeth. Waldner emphasises that this is not merely a marketing claim, but is supported by scientific evidence: “Two independent long-term clinical studies, conducted at the University of Düsseldorf and in collaboration with the Medical University of Graz, followed patients treated with Symbionic Teeth for periods of 9 and up to 12 years. In both studies, no peri-implantitis and only minimal occurrences of mucositis were reported – even in patients with risk factors for traditional dental Two thirds of patients with dental implants suffer from tissue inflammation – this is the sobering conclusion of a comprehensive literature review conducted by Swedish researchers. Specifically, every fifth implant patient develops peri-implantitis (chronic inflammation of the jawbone), while almost every second patient is affected by mucositis, an inflammation of the soft tissue (gums) that typically progresses to peri-implantitis if left untreated. With Symbionic Teeth, the Zurich-based manufacturing company Patent Medical offers an advanced tooth replacement technology that has been shown in independent studies to minimise the risk of these biological side effects, while promoting tissue health and long-term aesthetic stability. To learn more, we spoke with the company’s CEO and founder, Marco Waldner. Leaders in Dental Technology Innovation 2026 implant therapy such as periodontitis, diabetes, poor oral hygiene, cancer, or multiple sclerosis.” A further notable finding from the Düsseldorf study was that gum recession – a common problem associated with dental implants which causes grey material to become increasingly visible over time – is hardly an issue with Symbionic Teeth. Waldner notes: “As a result of the mucosal defence barrier, the soft tissue around Symbionic Teeth remains remarkably stable over time. All Symbionic Teeth followed up in this study showed an average gum recession of just 0.1 mm after 9 years – this is unheard of in the field of tooth replacement.” Study results like these are unrivalled in the field of tooth replacement and clearly distinguishes Symbionic Teeth from traditional dental implants. Of course, this is not to say that the dentists who have been utilising traditional dental implants for decades have done anything wrong, and Marco is quick to remind us that the “state of the art” at any given time is based on what is technologically available. The long-term aim is to ensure that patients worldwide receive the best possible replacement for their missing teeth – a solution that promotes the health of the oral tissue and remains aesthetically pleasing over time. Standing for this at every turn, the team behind Patent Medical and Patent™ Symbionic Teeth are fitting of being named as Leaders in Dental Technology Innovation 2026. Contact: Marco Waldner Company: Patent Medical Web Address: https://www.mypatent.com/ N Jul23706
RkJQdWJsaXNoZXIy MTUyMDQwMA==